Clinical Trial Search

Primary: Complete Response Rate at the End of Induction — 46 percentage of participants

Primary: Disease Recurrence Rate — 27.86; 40 percentage of patients with recurrence — p=0.01

Primary: Complete Response (CR) Rate in the Subset of Patients With Carcinoma in Situ (CIS) — 27 percentage of participants

Primary: Number of Participants With Complete Response at 3 Months — 26 Participants

Primary: Safety and Tolerability — 5; 2; 1; 1 Grade 1/2 event count (no grade 3+)

Primary: Number of Participants With Progression-free Survival at 6 Months — 3 Participants

Primary: Quality of Life Patient: The Functional Assessment of Cancer Therapy-Bladder Cancer-Cystectomy — 117.59; 118.70 Quality of Life Score — p=0.772

Primary: Arm A: Progression Free Survival (PFS) — 8 participants

Primary: Pathologic Response Rate (PaR) at Time of Radical Cystectomy. PaR is Defined as Absence of Residual MIBC at Cystectomy in the Surgical Specimen (Pathologic Down-staging…

Primary: Recurrence Rate at 2 Years — 112; 138; 170; 160 Participants — p=0.1094

Primary: Recurrence Rate at 2 Years — 112; 121; 183; 150 Participants — p=0.1068

Primary: Number of Participants With Freedom From Progression of Cancer at 4 Months — 20 Participants

Primary: Median Overall Survival — 13.9 months

Primary: Percentage of Participants Free From Radical Cystectomy at 3 Years — 88.2 percentage of participants

Primary: Recurrence Free Survival — 9.6; 16.4 months — p=0.056

Primary: Number of Participants Without Grade ≥ 3 Adverse Event, Graded According to NCI CTCAE Version 4.03 — 15; 14; 20 Participants

Primary: Percentage of Patients Without Distant Metastases by Three Years — 77.8; 84.0 percentage of participants

Primary: Percentage of Patients With Complete Pathologic Response After 3 Cycles of Treatment — 27.3 percentage of patients

Primary: Maximum Tolerated Dose (MTD) — 2 mg/kg Pembrolizumab

Primary: Overall Pathological Response Rate — 57.7 % of participants

Primary: Complete Response Rate at 3 Months — 39 percentage of participants

Primary: Cohort 1: Recurrence-Free Survival (RFS) — NA; 11.60 Months — p==0.0007

Primary: Median Yield of Robot Assisted and Second Look Open Pelvic Lymph Node Dissection to Compare the Lymph Node Yield Achieved — 43; 4 Nodes (Node Yield)

Primary: Number of Participants With Adverse Events — 2 Participants

Primary: Bladder Tumor Recurrence Rate — 41.37 percentage of subjects

Primary: Number of Participants With Grade 3, 4, and 5 Treatment Related Adverse Events — 0; 4; 3; 6 Participants

Primary: Percentage of Participants Without Recurrence (Recurrence-free Survival (RFS)) With Bacillus Calmette-Guerin (BCG) + PANVAC Compared With BCG Alone at 6 and 12 Months…

Primary: Evaluate the Efficacy for Treatment of Low/Intermediate- Risk Bladder Tumors, Assessing for the Clinical Response of the Marker Lesion — 13 Participants

Primary: Progression-Free Survival (PFS) — 2.8; 5.4; 1.6 months

Primary: The Number of Participants Experiencing an Unacceptable Level of Toxicity as Defined Below — 9; 6; 2; 4 Participants